A citation-based method for searching scientific literature

David M O'Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lucy Gilbert, Ignace Vergote, Lainie P Martin, Gina M Mantia-Smaldone, Antonio González Martin, Raquel Bratos, Richard T Penson, Karim Malek, Kathleen N Moore. Gynecol Oncol 2020
Times Cited: 23







List of co-cited articles
284 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
Johann S de Bono, Nicole Concin, David S Hong, Fiona C Thistlethwaite, Jean-Pascal Machiels, Hendrik-Tobias Arkenau, Ruth Plummer, Robert Hugh Jones, Dorte Nielsen, Kristian Windfeld,[...]. Lancet Oncol 2019
44
39

Trastuzumab emtansine for HER2-positive advanced breast cancer.
Sunil Verma, David Miles, Luca Gianni, Ian E Krop, Manfred Welslau, José Baselga, Mark Pegram, Do-Youn Oh, Véronique Diéras, Ellie Guardino,[...]. N Engl J Med 2012
39

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Kathleen N Moore, Lainie P Martin, David M O'Malley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd M Bauer, Rodrigo Ruiz-Soto, Michael J Birrer. J Clin Oncol 2017
89
39


Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
S Banerjee, A M Oza, M J Birrer, E P Hamilton, J Hasan, A Leary, K N Moore, B Mackowiak-Matejczyk, J Pikiel, I Ray-Coquard,[...]. Ann Oncol 2018
28
30

Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Kathleen N Moore, Hossein Borghaei, David M O'Malley, Woondong Jeong, Shelly M Seward, Todd M Bauer, Raymond P Perez, Ursula A Matulonis, Kelli L Running, Xiaoyan Zhang,[...]. Cancer 2017
41
30

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
Kathleen N Moore, Ignace Vergote, Ana Oaknin, Nicoletta Colombo, Susana Banerjee, Amit Oza, Patricia Pautier, Karim Malek, Michael J Birrer. Future Oncol 2018
35
30

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Raffit Hassan, George R Blumenschein, Kathleen N Moore, Alessandro D Santin, Hedy L Kindler, John J Nemunaitis, Shelly M Seward, Anish Thomas, Stella K Kim, Prabhu Rajagopalan,[...]. J Clin Oncol 2020
37
30

Folate receptor alpha as a tumor target in epithelial ovarian cancer.
Kimberly R Kalli, Ann L Oberg, Gary L Keeney, Teresa J H Christianson, Philip S Low, Keith L Knutson, Lynn C Hartmann. Gynecol Oncol 2008
248
26

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.
Colin D Weekes, Laetitia E Lamberts, Mitesh J Borad, Johannes Voortman, Robert R McWilliams, Jennifer R Diamond, Elisabeth G E de Vries, Henk M Verheul, Christopher H Lieu, George P Kim,[...]. Mol Cancer Ther 2016
57
26


Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
Lainie P Martin, Jason A Konner, Kathleen N Moore, Shelly M Seward, Ursula A Matulonis, Raymond P Perez, Ying Su, Anna Berkenblit, Rodrigo Ruiz-Soto, Michael J Birrer. Gynecol Oncol 2017
33
26


Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung-Bae Kim, Kenji Tamura, Fabrice Andre, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani,[...]. N Engl J Med 2020
315
26

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A Mayer, Linda T Vahdat, Sara M Tolaney, Steven J Isakoff, Jennifer R Diamond, Joyce O'Shaughnessy, Rebecca L Moroose, Alessandro D Santin, Vandana G Abramson,[...]. N Engl J Med 2019
210
26

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
J F Liu, K N Moore, M J Birrer, S Berlin, U A Matulonis, J R Infante, B Wolpin, K A Poon, R Firestein, J Xu,[...]. Ann Oncol 2016
44
21

Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials.
Joshua Seth Eaton, Paul E Miller, Mark J Mannis, Christopher J Murphy. J Ocul Pharmacol Ther 2015
91
21

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
Kevin J Hamblett, Peter D Senter, Dana F Chace, Michael M C Sun, Joel Lenox, Charles G Cerveny, Kim M Kissler, Starr X Bernhardt, Anastasia K Kopcha, Roger F Zabinski,[...]. Clin Cancer Res 2004
689
21

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
766
21

Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
Michael J Birrer, Kathleen N Moore, Ilaria Betella, Richard C Bates. J Natl Cancer Inst 2019
103
21

Antibody-drug conjugates in gynecologic malignancies.
Elizabeth K Lee, Joyce F Liu. Gynecol Oncol 2019
10
50

Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.
Joanna C Masters, Dana J Nickens, Dawei Xuan, Ronald L Shazer, Michael Amantea. Invest New Drugs 2018
67
21


Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
Ursula A Matulonis, Michael J Birrer, David M O'Malley, Kathleen N Moore, Jason Konner, Lucy Gilbert, Lainie P Martin, Todd M Bauer, Amit M Oza, Karim Malek,[...]. Clin Cancer Res 2019
10
50

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara, Krishnansu S Tewari, David M O'Malley,[...]. Lancet Oncol 2017
243
21

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
304
21

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.
Yelena V Kovtun, Charlene A Audette, Yumei Ye, Hongsheng Xie, Mary F Ruberti, Sara J Phinney, Barbara A Leece, Thomas Chittenden, Walter A Blättler, Victor S Goldmacher. Cancer Res 2006
252
21

Strategies and challenges for the next generation of antibody-drug conjugates.
Alain Beck, Liliane Goetsch, Charles Dumontet, Nathalie Corvaïa. Nat Rev Drug Discov 2017
834
21


A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.
Marc Damelin, Alexander Bankovich, Jeffrey Bernstein, Justin Lucas, Liang Chen, Samuel Williams, Albert Park, Jorge Aguilar, Elana Ernstoff, Manoj Charati,[...]. Sci Transl Med 2017
67
21

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, Sibylle Loibl, Eleftherios P Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo,[...]. N Engl J Med 2019
588
21

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Kathleen N Moore, Michael J Birrer, Jim Marsters, Yulei Wang, YounJeong Choi, Stephanie Royer-Joo, Vanessa Lemahieu, Katy Armstrong, Julie Cordova, Divya Samineni,[...]. Gynecol Oncol 2020
6
83

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
E L Sievers, R A Larson, E A Stadtmauer, E Estey, B Löwenberg, H Dombret, C Karanes, M Theobald, J M Bennett, M L Sherman,[...]. J Clin Oncol 2001
604
17

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
Maria Quanz, Urs B Hagemann, Sabine Zitzmann-Kolbe, Beatrix Stelte-Ludwig, Sven Golfier, Cem Elbi, Dominik Mumberg, Karl Ziegelbauer, Christoph A Schatz. Oncotarget 2018
20
20

Antibody conjugate therapeutics: challenges and potential.
Beverly A Teicher, Ravi V J Chari. Clin Cancer Res 2011
239
17

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Jose F Ponte, Olga Ab, Leanne Lanieri, Jenny Lee, Jennifer Coccia, Laura M Bartle, Marian Themeles, Yinghui Zhou, Jan Pinkas, Rodrigo Ruiz-Soto. Neoplasia 2016
34
17

Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
Paul J Carter, Greg A Lazar. Nat Rev Drug Discov 2018
302
17

Acquired Resistance to Antibody-Drug Conjugates.
Denis M Collins, Birgit Bossenmaier, Gwendlyn Kollmorgen, Gerhard Niederfellner. Cancers (Basel) 2019
37
17

Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.
Kristina Levan, Matin Mehryar, Constantina Mateoiu, Per Albertsson, Tom Bäck, Karin Sundfeldt. BMC Cancer 2017
11
36


Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Sven Golfier, Charlotte Kopitz, Antje Kahnert, Iring Heisler, Christoph A Schatz, Beatrix Stelte-Ludwig, Anke Mayer-Bartschmid, Kerstin Unterschemmann, Sandra Bruder, Lars Linden,[...]. Mol Cancer Ther 2014
126
17

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.
A W Tolcher, S Sugarman, K A Gelmon, R Cohen, M Saleh, C Isaacs, L Young, D Healey, N Onetto, W Slichenmyer. J Clin Oncol 1999
179
17

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Olga Ab, Kathleen R Whiteman, Laura M Bartle, Xiuxia Sun, Rajeeva Singh, Daniel Tavares, Alyssa LaBelle, Gillian Payne, Robert J Lutz, Jan Pinkas,[...]. Mol Cancer Ther 2015
77
17

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Yu-Tzu Tai, Patrick A Mayes, Chirag Acharya, Mike Y Zhong, Michele Cea, Antonia Cagnetta, Jenny Craigen, John Yates, Louise Gliddon, William Fieles,[...]. Blood 2014
235
17

Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.
Carla Ríos-Luci, Sara García-Alonso, Elena Díaz-Rodríguez, Mercedes Nadal-Serrano, Joaquín Arribas, Alberto Ocaña, Atanasio Pandiella. Cancer Res 2017
56
17

Cleavable linkers in antibody-drug conjugates.
Jonathan D Bargh, Albert Isidro-Llobet, Jeremy S Parker, David R Spring. Chem Soc Rev 2019
83
17

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, Monica Mita, John W Moroney, Robert Holloway, Linda Van Le, Jasgit C Sachdev, Eloise Chapman-Davis, Gerardo Colon-Otero,[...]. JAMA Oncol 2019
135
17

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Andrea Varga, Sarina Piha-Paul, Patrick A Ott, Janice M Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane Ruman, Daniela Matei. Gynecol Oncol 2019
81
17

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Joyce F Liu, Christina Herold, Kathryn P Gray, Richard T Penson, Neil Horowitz, Panagiotis A Konstantinopoulos, Cesar M Castro, Sarah J Hill, Jennifer Curtis, Weixiu Luo,[...]. JAMA Oncol 2019
52
17

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
606
17


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.